Clinical Trial Update: A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the long-term safety of rimegepant for acute treatment of migraine in Chinese participants has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Rimegepant (Nurtec ODT) (Rimegepant)

Snippet

Sponsor: Pfizer | Conditions: Acute Migraine | Phase 3 | Status: COMPLETED | Results posted: 2025-02-20